Threats to the future of cardiovascular research

The Lancet

Volumn 373, Issue 9667, 2009, Pages 875-876

  Sheridan, Desmond John ^a   Heusch, Gerd ^b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RESEARCH; FUNDING; HEALTH CARE DELIVERY; MORBIDITY; MORTALITY; PRIORITY JOURNAL;

EID: 61849113384     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60525-0     Document Type: Note

References (9)

1. Herper M. The Pfizer memo. Forbes (Sept 30, 2008). http://www.forbes.com/business/2008/09/30/pfizer-drug-agenda-biz-bizhealth-cx_mh_0930pfizermemo.html http://www.forbes.com/business/2008/09/30/pfizer-drug-agenda-biz-bizhealth-cx_mh_0930pfizermemo.html (accessed March 2, 2009).
2. Kaplan W., and Laing R. Priority medicines for Europe and the world (November, 2004). http://whqlibdoc.who.int/hq/2004/WHO_EDM_PAR_2004.7.pdf (accessed March 2, 2009).
3. Oxtoby K. Professional roles blurring. BMJ [Careers] 338 (2009) 11-12
4. Sheridan D.J. Reversing the decline of academic medicine in Europe. Lancet 367 (2006) 1698-1701
5. Ley T.J., and Rosenberg L.E. The physician-scientist career pipeline in 2005: build it, and they will come. JAMA 294 (2005) 1343-1351
6. Heusch G. Viewpoint: crisis in German academic medicine. Circulation 117 (2008) f67-f69
7. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., and Murray C.J.L. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367 (2007) 1747-1757
8. Stuckler D., King L., Robinson H., and McKee M. WHO's budgetary allocations and burden of disease: a comparative analysis. Lancet 372 (2008) 1563-1569
9. Garnier J.P. Rebuilding the R&D engine in big pharma. Harv Bus Rev 86 (2008) 68-76